glp-1 afib Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 Genetics: How Genes Affect

A.GockeA

Based on a receptor-interaction model, structural modifications of the benzene and pyridine rings led to the identification of compound 26 (Figure 5), which includes a 2,4-dichlorophenyl group at two positions, as a potent (IC 50 = 0.13 M), selective (DPP-8/DPP-4 = 215, DPP-9/DPP-4 = 192), and in vivo efficacious DPP-4 inhibitor

Rubino, D., Abrahamsson, N., Davies, M., et al

The Potential Pros of Microdosing GLP-1s The true potential benefit of microdosing may have nothing to do with weight loss

Unfortunately, weight loss isnt as simple as filling a prescription. In the US, seven out of ten adults and three out of ten children are overweight or are living with obesity